Specialist interest article
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia

https://doi.org/10.1016/0277-5379(91)90181-CGet rights and content

Abstract

255 patients with acute non-lymphoid leukaemia (ANLL), observed between October 1984 and June 1987, entered a chemotherapy regimen consisting of induction therapy with cytarabine in combination with idarubicin (IDA/ARA) or daunorubicin (DNR/ARA), followed by consolidation with four courses of IDA+ARA plus 6-thioguanine (6-TG) or DNR+ARA+6-TG and a 6 month maintenance therapy with 6-TG and ARA. The median age was 62 years (range 55–78 years) and 33 were aged more than 70 years. The treatment groups were comparable for median age, FAB type, performance status and initial blood counts. 249 patients were randomised, 124 to the IDA/ARA arm and 125 to the DNR/ARA arm. Complete remission was achieved in 50 patients (40%) on the IDA/ARA treatment program and 49 patients (39%) on DNR/ARA. No definite differences were found between patients receiving IDA/ARA and those treated with DNR/ARA as far as complete response (CR), overall survival, failure free and relapse free survival are concerned. 74% of the complete responders in the IDA/ARA arm and 51% in the DNR/ARA arm achieved CR after a single course of treatment. Resistant leukaemia was observed in 13.7% of the patients in the IDA/ARA arm and in 31.2% in the DNR/ARA one, whereas hypoplastic death occurred in 29% and 14.4%, respectively. In conclusion, our data failed to show any advantage of idarubicin over daunorubicin even though there is some evidence that IDA, despite the higher toxicity, is more rapid in eradicating leukaemia as proved by the higher CR rate obtained after one course of induction.

References (27)

  • AM Casazza et al.

    Antileukemic activity of 4-demethoxydaunorubicin in mice

    Tumori

    (1980)
  • AM Casazza et al.

    Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin

  • AM Carella et al.

    4-demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias

  • Cited by (95)

    • Critical Updates to the Leukemia Stem Cell Model

      2016, Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance
    • Treatment of Acute Myeloid Leukemia in Elderly Patients—A Therapeutic Dilemma

      2016, Journal of the American Medical Directors Association
      Citation Excerpt :

      Several studies carried out more than 2 decades ago established an induction regimen of 45 mg/m2 intravenous daunorubicin for 3 days combined with 100 mg/m2 cytarabine by continuous infusion for 7 days (frequently referred to as the “7 + 3” regimen)35–38 as the most commonly applied treatment standard in the US and worldwide. Interestingly, for patients younger than 55–60 years of age, multiple prospective randomized studies demonstrated that other anthracyclines were at least as effective as daunorubicin at a dose of 45 mg/m2.39–47 However, the results for patients older than 55–60 years of age are equivocal.

    View all citing articles on Scopus

    Presented in part at the 20th Congress of the International Society of Hematology, Milan, 1988.

    View full text